NYSE:ALR Alere (ALR) Stock Price, News & Analysis → Trump’s “Tax Free” Retirement Strategy (From Gold Safe Exchange) (Ad) Free ALR Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$1.32▼$1.3250-Day Range N/A52-Week Range$34.41▼$51.00VolumeN/AAverage Volume40,839 shsMarket Capitalization$43.05 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Alere alerts: Email Address Ad Porter & CompanyAI to Meet the Same Fate as EVs? When these tech bubbles burst, they invariably leave investors disillusioned by their losses. Now, many worry a similar fate is awaiting AI. And one man, legendary financial analyst Porter Stansberry, who called Nvidia at $11… Simply click here to read Porter’s warning on The Big AI Die-Up now. About Alere Stock (NYSE:ALR)Alere Inc. is a provider of health information through diagnostic tests. The Company's segments include professional diagnostics, consumer diagnostics, and corporate and other. The professional diagnostics segment includes an array of diagnostic test products and other in vitro diagnostic tests marketed to medical professionals and laboratories for detection of diseases and conditions within its areas of focus. The consumer diagnostics segment consists primarily of manufacturing operations related to its role as the exclusive manufacturer of products for SPD Swiss Precision Diagnostics (SPD), its joint venture with The Procter & Gamble Company (P&G). The Company's professional diagnostic solutions allow patients and their healthcare providers to work together to manage patients' conditions over the continuum of care, from the hospital to home. The Company offers lines of drugs-of-abuse tests, reagent systems and laboratory testing options.Read More Ad Porter & CompanyAI to Meet the Same Fate as EVs? When these tech bubbles burst, they invariably leave investors disillusioned by their losses. Now, many worry a similar fate is awaiting AI. And one man, legendary financial analyst Porter Stansberry, who called Nvidia at $11… Simply click here to read Porter’s warning on The Big AI Die-Up now. ALR Stock News HeadlinesDecember 28, 2023 | morningstar.comAlro SA ALRApril 18, 2023 | thestreet.comAlere (ALR) Stock Plummets, Rejects Abbott's Request to End MergerMarch 28, 2024 | Porter & Company (Ad)AI to Meet the Same Fate as EVs? When these tech bubbles burst, they invariably leave investors disillusioned by their losses. Now, many worry a similar fate is awaiting AI. And one man, legendary financial analyst Porter Stansberry, who called Nvidia at $11… April 9, 2023 | yahoo.comTrek's latest aluminium Émonda ALR is lighter and racier than beforeFebruary 3, 2023 | finance.yahoo.comABP Acquisition to Acquire AlerisLife for $1.31 Per ShareNovember 2, 2022 | finance.yahoo.comAlerisLife Inc. Announces Third Quarter 2022 ResultsOctober 17, 2022 | finance.yahoo.comAlerisLife Announces the Appointment of Philip Benjamson as a Senior Vice President and Chief Operating OfficerOctober 16, 2022 | seekingalpha.comAbbott Q3 Earnings Preview: I'm Still Not A Buyer (NYSE:ABT) - Seeking AlphaMarch 28, 2024 | Porter & Company (Ad)AI to Meet the Same Fate as EVs? When these tech bubbles burst, they invariably leave investors disillusioned by their losses. Now, many worry a similar fate is awaiting AI. And one man, legendary financial analyst Porter Stansberry, who called Nvidia at $11… October 11, 2022 | prnewswire.comCritical Care Diagnostics Market to Exceed US$ 1.7 Billion by 2031 Amid Rising Prevalence of Chronic Diseases - PR NewswireOctober 11, 2022 | prnewswire.comDrug Screening Market is expected to generate a revenue of USD 22.16 Billion by 2030, Globally, at 10.6% CAGR: Verified Market Research® - PR NewswireOctober 7, 2022 | benzinga.comAt 5.4% CAGR, Arbovirus Testing Market Size is Expected to Reach US$ 1919.7 Mn by 2030 | Market Expected - BenzingaOctober 5, 2022 | benzinga.comOutlook on the Isothermal Nucleic Acid Amplification Technology Global Market to 2030 - Featuring Alere, - BenzingaOctober 5, 2022 | finance.yahoo.comAlerisLife Inc. Third Quarter 2022 Conference Call Scheduled for Thursday, November 3rdOctober 5, 2022 | finance.yahoo.comGlobal Infectious Disease In Vitro Diagnostics Market Report (2022 to 2030) - High Demand for PoC Facilities is Driving Growth - Yahoo FinanceOctober 5, 2022 | globenewswire.comOutlook on the Isothermal Nucleic Acid Amplification Technology Global Market to 2030 - Featuring Alere, Biomerieux and Lucigen Among Others - GlobeNewswireSeptember 19, 2022 | finance.yahoo.comAlerisLife Announces the Appointment of Heather Pereira as Senior Vice President, Chief Financial Officer and TreasurerSeptember 9, 2022 | finance.yahoo.comAlerisLife Inc. (ALR)August 13, 2022 | investing.comALR_pb Historical DataAugust 6, 2022 | finance.yahoo.comAlerisLife (NASDAQ:ALR) adds US$18m to market cap in the past 7 days, though investors from five years ago are still down 89%August 3, 2022 | nasdaq.comAlere Inc. Q2 Loss decreases, but misses estimatesAugust 3, 2022 | finance.yahoo.comAlerisLife Inc. Announces Second Quarter 2022 ResultsJuly 22, 2022 | reuters.comColumn: Aluminium producers feel the margin pain as price slumpsJuly 6, 2022 | finance.yahoo.comAlerisLife Inc. Second Quarter 2022 Conference Call Scheduled for Thursday, August 4thJune 28, 2022 | finance.yahoo.comAlerisLife Provides a Business UpdateJune 14, 2022 | streetinsider.comMainz Biomed Appoints Vice President of Clinical Affairs to Lead US Clinical Studies in Support of FDA Submission - StreetInsider.comJune 14, 2022 | finance.yahoo.comMainz Biomed Appoints Vice President of Clinical Affairs to Lead US Clinical Studies in Support of FDA Submission - Yahoo FinanceSee More Headlines Receive ALR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Alere and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/04/2016Today3/28/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorMedical Industry Skilled nursing care facilities Sub-IndustryHealth Care Supplies Current SymbolNYSE:ALR CUSIP01449J10 CIK1145460 Webwww.alere.com Phone+1-781-6473900Fax617-796-8385Employees10,400Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($1.20) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-29,920,000.00 Net Margins-5.34% Pretax Margin-5.29% Return on Equity-20.78% Return on Assets-9.02% Debt Debt-to-Equity Ratio0.45 Current Ratio1.58 Quick Ratio1.58 Sales & Book Value Annual Sales$934.59 million Price / Sales0.05 Cash FlowN/A Price / Cash FlowN/A Book Value$5.72 per share Price / Book0.23Miscellaneous Outstanding Shares32,610,000Free Float29,870,000Market Cap$43.05 million OptionableOptionable Beta0.85 13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.Get This Free Report Key ExecutivesGregg J. PowersIndependent Chairman of the BoardNamal NawanaPresident, Chief Executive Officer, DirectorJames F. HinrichsChief Financial Officer, Executive Vice PresidentDaniella CrampGlobal President - Cardiometabolic Business UnitSanjay MalkaniGlobal President - ToxicologyAvi PelossofGlobal President - Infectious Disease Business UnitEllen Chiniara J.D.Senior Vice President, General Counsel, Chief Ethics and Compliance Officer, SecretaryRobert HargadonSenior Vice President - Global Human ResourcesJohn Bridgen Ph.D.Senior Vice President - Business DevelopmentMark GladwellSenior Vice President - Global OperationsMore ExecutivesKey CompetitorsModular MedicalNASDAQ:MODDCandel TherapeuticsNASDAQ:CADLGyre TherapeuticsNASDAQ:GYREPixie Dust TechnologiesNASDAQ:PXDTTiziana Life SciencesNASDAQ:TLSAView All Competitors ALR Stock Analysis - Frequently Asked Questions How were Alere's earnings last quarter? Alere Inc. (NYSE:ALR) announced its quarterly earnings results on Friday, November, 4th. The medical research company reported $0.19 EPS for the quarter, missing the consensus estimate of $0.54 by $0.35. The medical research company earned $582 million during the quarter, compared to analyst estimates of $605.50 million. Alere had a negative net margin of 5.34% and a negative trailing twelve-month return on equity of 20.78%. Alere's revenue for the quarter was down 3.6% compared to the same quarter last year. During the same quarter in the previous year, the business posted ($0.10) EPS. What other stocks do shareholders of Alere own? Based on aggregate information from My MarketBeat watchlists, some companies that other Alere investors own include Morgan Stanley (MS), BioTelemetry (BEAT), Abbott Laboratories (ABT), FireEye (FEYE), Twitter (TWTR), Allergan (AGN), AEGR (AEGR), Ashmore Group (ASHM), Chembio Diagnostics (CEMI) and Capitala Finance (CPTA). Who are Alere's major shareholders? Alere's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Concourse Financial Group Securities Inc. (0.00%). View institutional ownership trends. This page (NYSE:ALR) was last updated on 3/28/2024 by MarketBeat.com Staff From Our PartnersTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeGrab Your Free Bitcoin Today!Crypto Swap ProfitsTop Project Outperforms BTC in 2023…Crypto 101 MediaMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm Press“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisoryMost important medical advance in 100 yearsThe Oxford ClubFed launches fourth dollar overhaulStansberry Research Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Alere Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.